Prostate Cancer

Through a comprehensive and systematic search of the best available evidence, the Neoplastic Diseases Task Force developed 20 recommendations on screening and risk factor assessment for 10 specific questions on neoplastic diseases. These recommendations serve as guidance on screening neoplastic diseases at the primary care level.

In conclusion, curcumin shows great promise in improving prostate cancer treatment by targeting key cancer pathways and enhancing the effects of existing therapies. While its potential is clear, further clinical studies are needed to refine its use and ensure its effectiveness in real-world applications.

PSAD-based triage, particularly at ≥0.15 ng/mL/cc, showed superior diagnostic utility and may support safe biopsy deferral in selected cases. Prospective validation in broader non-referral settings is warranted.

Despite a history of recurrent urinary tract infections (UTIs) associated with mono-J catheters, the frequency of UTIs did not increase during therapy with IFX. This case indicates that infliximab may represent an effective therapeutic option for non-CD-related fistulas when there are no other therapeutic options available.

This study is the first to reveal PAH as a metabolic immunomodulator and an independent prognostic factor in postoperative PC patients. PAH may affect prostate cancer outcomes by altering the tumor microenvironment.

Biological evaluation identified compound 39 as an active degrader that induced substantial AR degradation in LNCaP prostate cancer cells. This work supports the feasibility of recruiting HSP70 for TPD and provides a molecular tool for AR-degradation research, thereby expanding the TPD toolbox for future drug discovery.

P2, N=30, Not yet recruiting, Deepak Kilari | Trial completion date: Dec 2027 --> Jul 2029 | Trial primary completion date: Dec 2026 --> Jul 2028

P2, N=200, Recruiting, Case Comprehensive Cancer Center | Trial completion date: Apr 2028 --> Dec 2028 | Trial primary completion date: Apr 2028 --> Dec 2028

P=N/A, N=434, Recruiting, CHU de Quebec-Universite Laval | Not yet recruiting --> Recruiting | Initiation date: Feb 2026 --> May 2026

In men with low-risk PCa under AS, Stockholm3 may enhance risk stratification and reduce unnecessary biopsies. Prostate-specific antigen density and multiparametric magnetic resonance imaging showed comparable performance, with Stockholm3 providing a potentially practical blood-based complement in a multimodal strategy.

Furthermore, ERRγ functionally competed with major transcriptional coactivators, including steroid receptor coactivators-3 (SRC-3) and p300, thereby attenuating coactivator-enhanced AR-dependent transcription. Collectively, these findings demonstrate that ERRγ functions as a novel corepressor of AR by destabilizing receptor conformation and blocking coactivator recruitment, providing new mechanistic insights into the regulation of AR-mediated transcription.